Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Payables: 2020-2024

Historic Payables for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $5.7 million.

  • SAB Biotherapeutics' Payables fell 0.43% to $6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.9 million, marking a year-over-year decrease of 1.59%. This contributed to the annual value of $5.7 million for FY2024, which is 25.75% down from last year.
  • According to the latest figures from FY2024, SAB Biotherapeutics' Payables is $5.7 million, which was down 25.75% from $7.7 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Payables registered a high of $14.3 million during FY2021, and its lowest value of $5.7 million during FY2024.
  • In the last 3 years, SAB Biotherapeutics' Payables had a median value of $7.7 million in 2023 and averaged $8.1 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Payables surged by 76.11% in 2021, and later fell by 27.57% in 2023.
  • SAB Biotherapeutics' Payables (Yearly) stood at $8.1 million in 2020, then skyrocketed by 76.11% to $14.3 million in 2021, then fell by 24.99% to $10.7 million in 2022, then fell by 27.57% to $7.7 million in 2023, then decreased by 25.75% to $5.7 million in 2024.